Clinical Trials Logo

Wild Type BRAF Stage IV Melanoma clinical trials

View clinical trials related to Wild Type BRAF Stage IV Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01605162 Terminated - Clinical trials for Unresectable Stage III Melanoma

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Start date: May 2012
Phase: Phase 2
Study type: Interventional

This is a Phase 2, open-label, multicenter study to assess the PFS-6m of E7016 at the selected dose of 320-mg once daily (QD) in combination with 150-mg/m2 of Temozolomide (TMZ) in subjects with wt BRAF Stage IV or unresectable Stage III melanoma with disease progression. Eligible subjects must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST).